Navigation Links
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
Date:12/10/2007

on, women treated with Vidaza should not nurse.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase 2 monotherapy and Phase 1/2 combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290, an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Vidaza and MGCD0103. Such statements are based on current expectations and involve a number of known and un
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... a form of acupuncture where a small ... needles produces significant improvements in fatigue, anxiety ... for early stage breast cancer patients experiencing joint ... (AIs) to treat breast cancer. The results of ... by researchers at the Perelman School of Medicine ...
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that ... medicine specialist. Alison Freeman wanted to show her patients some ... interested in finding out more about this method can easily ... it is currently available in online format. , In the ... herbal medicine tips that can help them achieve a cure ...
(Date:7/29/2014)... Diabetes is a common condition diagnosed in millions of ... increased, while the production of insulin is decreased. , ... is needed by the body to regulate blood sugar levels. ... dangerous, as there are numerous complications that can be developed ... and read a complex review of Matt Traverso's new book ...
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily Gossip ... the new method was created for any sufferer who is ... , The author of the new program, Sarah Summer, ... Sarah actually suffered from yeast infection, too. Actually, this is ... cure for this problem. , The Natural Cure ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica ... new method of naturally overcoming sciatica, in less than ... method ensure sufferers that the cure is simple to ... The new method is described as very fast, as ... an 8 minutes per day treatment plan. , ...
Breaking Medicine News(10 mins):Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... September 2 According to a new,market research report, ... ), the global emerging lighting technologies,market is expected to ... of 7.9% from 2009 to 2014. The North American ... total revenues. , Browse 109 ...
... , TUESDAY, Sept. 1 (HealthDay News) -- Monkeys ... can appreciate music inspired by the sounds they themselves ... monkey calls, the animals moved less often. If they ... became anxious. , This may not sound surprising. But ...
... , , TALLAHASSEE, Fla., Sept. 2 ... signed a sponsorship agreement with LearnSomething to test the impact of ... , In a select number of retail stores for ... in aisles and at endcaps. From an LCD screen with ten ...
... Company Signs Agreement to Sell MDS Analytical Technologies to ... of Sale Proceeds to Shareholders;, Announces Intent to ... - MDS Inc. (TSX: MDS; NYSE: MDZ ), a ... markets, today announced that it has entered into an agreement to ...
... , MOUNTAIN VIEW, Calif., Sept. 2 MAP ... in the following events in September: , , , ... 11, at 10:20 a.m. ET in Boston, 14th Congress of ... Late-Breaking oral platform presentation on Saturday, September 12, at, ...
... , , LONDON, Sept. ... of information system in place, very few have a fully ... adoption rate of HIS solutions in 2008 in Europe varied ... 95.0 per cent in Scandinavia. Increasing accountability pressures on the ...
Cached Medicine News:Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 2Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 3Health News:Scientists Make Sweet Monkey Music 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 3Health News:MDS Announces Strategic Repositioning 2Health News:MDS Announces Strategic Repositioning 3Health News:MDS Announces Strategic Repositioning 4Health News:MDS Announces Strategic Repositioning 5Health News:MDS Announces Strategic Repositioning 6Health News:MDS Announces Strategic Repositioning 7Health News:MDS Announces Strategic Repositioning 8Health News:MDS Announces Strategic Repositioning 9Health News:MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 2Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 3
(Date:7/29/2014)... NEW YORK , July 29, 2014 /PRNewswire-iReach/ ... on the basis of products, methods, applications, end ... register highest growth in the microbial identification market. ... in consumable costs (per test) and the time ... accuracy and continuous technological advancements. Furthermore, genotypic methods ...
(Date:7/29/2014)... July 29, 2014  Express Scripts Holding Company (Nasdaq: ... income attributable to Express Scripts stockholders of $515.2 million, ... share, as detailed in Table 4, was $1.23 for ... well positioned to serve our clients with scale, alignment and ... improve the health outcomes of our members," stated George Paz, ...
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31
... for Healthcare ... Professionals, VOORHEES, ... that causes disease with a wide spectrum of,severity, ranging from mild ... to 20% of patients who develop an initial,case of CDI.(1) These ...
... Israel, July 1 Applisonix LTD (TASE:,APLS), a ... market, announced today that the test conducted using ... average hair,reduction of 38%, which positions its efficacy ... Applisonix, co-CEOs, Mr. Alon Goren and Mr. Uri ...
Cached Medicine Technology:Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment 2
... Solution (Palm OS) makes the patient appointment, ... functionality of the MedPlexus System accessible ... time and have access to data that ... - review appointment schedules, create super bills ...
MD Coder v 6.0 is a charge capture for the Palm OS and Pocket PC operating systems. We have integrated the feedback from hospitals and physicians. MD Coder v 6.0 comes in three versions: Physician Ba...
A Palm Pilot and Desktop utility that you can use. Search for ICD codes in your office on your computer or in the field using your Palm Pilot....
... the numerical list of disease and code ... or Pocket PC PDA or Smartphone. The ... Modification (ICD-9-CM) is based on the World ... Diseases (ICD-9). ICD-9-CM is the official system ...
Medicine Products: